Can-Fite BioPharma Ltd. (CANF)

Market Cap	10.52M
Revenue (ttm)	743,000
Net Income (ttm)	-7.63M
Shares Out	5.48M
EPS (ttm)	-0.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,746
Open	1.940
Previous Close	1.940
Day's Range	1.910 - 1.970
52-Week Range	1.710 - 3.330
Beta	0.91
Analysts	Strong Buy
Price Target	18.00 (+837.5%)
Earnings Date	May 30, 2024

About CANF

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 8
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CANF

Financial Performance

In 2023, CANF's revenue was 743,000, a decrease of -8.27% compared to the previous year's 810,000. Losses were -7.63 million, -24.96% less than in 2022.

Financial numbers in ILS

Analyst Forecast

According to one analyst, the rating for CANF stock is "Strong Buy" and the 12-month stock price forecast is $18.0.

Price Target

$18.0

(837.50% upside)

Analyst Consensus: Strong Buy